Vanguard Group Inc. Has $118.94 Million Position in Kiniksa Pharmaceuticals International, plc $KNSA

Vanguard Group Inc. cut its stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 2.2% during the third quarter, HoldingsChannel reports. The fund owned 3,063,135 shares of the company’s stock after selling 68,467 shares during the quarter. Vanguard Group Inc.’s holdings in Kiniksa Pharmaceuticals International were worth $118,942,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Savant Capital LLC acquired a new position in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $398,000. Aberdeen Group plc acquired a new stake in shares of Kiniksa Pharmaceuticals International during the 3rd quarter valued at about $6,163,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at approximately $1,480,000. Essex Investment Management Co. LLC increased its holdings in Kiniksa Pharmaceuticals International by 44.3% in the third quarter. Essex Investment Management Co. LLC now owns 247,301 shares of the company’s stock worth $9,603,000 after buying an additional 75,864 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in Kiniksa Pharmaceuticals International by 62.2% during the second quarter. Franklin Resources Inc. now owns 108,574 shares of the company’s stock valued at $3,004,000 after acquiring an additional 41,632 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $47.27 on Thursday. The stock’s 50-day moving average is $43.16 and its 200-day moving average is $40.09. The company has a market cap of $3.58 billion, a P/E ratio of 63.88 and a beta of 0.06. Kiniksa Pharmaceuticals International, plc has a 52-week low of $18.25 and a 52-week high of $49.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s revenue for the quarter was up 65.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.12) EPS. As a group, equities analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Insider Activity

In related news, CFO Mark Ragosa sold 17,845 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $43.28, for a total transaction of $772,331.60. Following the completion of the transaction, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. This represents a 59.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Barry D. Quart sold 2,690 shares of the stock in a transaction on Thursday, February 12th. The shares were sold at an average price of $45.00, for a total transaction of $121,050.00. Following the completion of the sale, the director directly owned 12,546 shares of the company’s stock, valued at approximately $564,570. This trade represents a 17.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 123,623 shares of company stock valued at $5,236,389. 53.48% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

KNSA has been the subject of a number of analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Wedbush upped their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Canaccord Genuity Group assumed coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 target price on the stock. Finally, Zacks Research raised Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and an average price target of $55.29.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.